Treatment of Sexual Impairment and Erectile Failure with Arginine and Natural Supplies as Alternative to Sildenafil

1998 ◽  
Vol 65 (1_suppl) ◽  
pp. 25-27
Author(s):  
F. Mantovani ◽  
E. Patelli ◽  
F. Colombo
Keyword(s):  
Placebo Group ◽  
Sexual Function ◽  
Royal Jelly ◽  
Young Patients ◽  
Pharmacological Therapy ◽  
The Other ◽  
Double Blind ◽  
The Third ◽  
Interesting Possibility ◽  
Male Sexual Function

Impairment of male sexual function is often associated with reduction in libido and can also occur at a relatively young age (30–50 years). In these cases pharmacological treatment may be clinically important. The effectiveness of the association L-arginine, fluid ginseng-guaranà and dried royal jelly was assessed. The choice of active ingredients was mainly based on their complete lack of side effects. A comparative double blind experimental model of research was used, patients being randomised into two groups. L-arginine HCL 2 g x 3 daily, dried royal jelly 200 mg, fluid ginseng 200 mg and guaranà 40 mg were given to 50 patients for two months. The other patients received a placebo. Clinical examination was repeated at monthly intervals. Treatment resulted in a significant improvement of the “libido intensity” symptom at the second and third control. An improvement in erectile maintenance was also noted at the third visit and, to a lesser extent, in all the other symptoms, whereas the placebo group showed non appreciable improvement. Results of this clinical study confirm the effectiveness of pharmacological therapy with arginine and natural supplies in young patients with impaired sexual function. There is also the interesting possibility of cyclic repetition of the treatment throughout the year in order to reinforce results and prevent a relapse.

Erectile dysfunction in psychiatric patients

2011 ◽  
Vol 26 (S2) ◽  
pp. 1548-1548
Author(s):  
M. Ladea ◽  
M. Bran ◽  
C.M. Barbu ◽  
M.C. Sarpe
Keyword(s):  
Erectile Dysfunction ◽  
Sexual Function ◽  
Antipsychotic Medication ◽  
Sexual Desire ◽  
Erectile Function ◽  
Psychotic Disorders ◽  
Psychiatric Patients ◽  
Young Patients ◽  
Male Sexual Function

IntroductionErectile dysfunction (ED) is defined as the inability to achieve or maintain an erection sufficient for sexual activity.ObjectivesED is a common condition in psychiatric patients, which can modify their quality of life.AimsThe aim of this study is to assess the prevalence and the severity of ED in psychiatric patients.MethodsThis naturalistic, observational study was conducted during a six months period. The International Index of Erectile Function (IIEF) 15-item questionnaire was used to assess 144 male inpatients with different psychiatric disorders. IIEF is a brief, cross-culturally valid, self-administered scale for detecting treatment-related changes in patients with erectile dysfunction and addresses the relevant domains of male sexual function: erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction. The patients were analyzed by age, psychiatric diagnosis, medication, IIEF scores at admission.ResultsThen mean age was 36.4 years. The lot included 44 patients with Psychotic Disorders, 68 with Mood Disorders, 21 with Alcohol Dependence, 11 with Personality Disorders. Severe ED was registered in 38% of investigated patients, which determined abandon of sexual attempts in 57% of cases; 12% had moderate ED, 15% had mild to moderate ED, 18% had mild ED and 17% had normal sexual function. No orgasm was reported in 32% of patients and 37% had no sexual desire. Under treatment with antipsychotic medication 78% had severe or moderate ED.ConclusionsSevere ED was correlated with age, also being seen in young patients. ED was correlated with depression, schizophrenia and antipsychotic medication.

scholarly journals Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial

2022 ◽  
Author(s):  
Maria Eugenia-Toledo-Romani ◽  
Mayra Garcia-Carmenate ◽  
Leslyhana Verdecia-Sanchez ◽  
Suzel Perez-Rodriguez ◽  
Meybis Rodriguez-Gonzalez ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Placebo Group ◽  
Neutralizing Antibodies ◽  
Seroconversion Rate ◽  
Serious Adverse Events ◽  
Double Blind ◽  
The Third ◽  
Functional Antibodies ◽  
Dose Trial ◽  
To Receive

Background: We report results of immunogenicity, safety and reactogenicity of SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults in a phase IIb clinical trial. Method: This phase IIb trial was designed as parallel, multicentre, adaptive, double blind, randomized and placebo-controlled. Subjects (N=810) aged 19-80 years were randomized to receive two doses of the recombinant SARS CoV-2 receptor binding domain (RBD) conjugated to tetanus toxoid (SOBERANA 02) and a third dose of dimeric RBD (SOBERANA Plus) 28 days apart; two production batches of active ingredient of SOBERANA 02 were evaluated. Primary outcome was the percentage of seroconverted subjects with ≥4-fold the anti-RBD IgG concentration. Secondary outcomes were safety, reactogenicity and neutralizing antibodies. Results: Seroconversion rate in vaccinees was respectively 76.3 and 96.8% after two or three doses, compared with 7.3% in placebo group. Anti-RBD IgG increased significantly after first and second dose of SOBERANA 02 respect to placebo group; and the third dose with SOBERANA Plus boosts the response compared to the second dose. Neutralizing IgG antibodies were detected against D614G and VOCs α, β and δ. Specific and functional antibodies were detected until 7-8 months after the third dose. The frequency of serious adverse events (AEs) associated with vaccination was very low (0.1%); with only one serious AE consistent with vaccination. Local pain was the most frequent AE. Conclusions: Two doses of SOBERANA 02 were well tolerated, safe an immunogenic in adults aged 19-80 years old. The heterologous combination with a third dose of SOBERANA Plus increased neutralizing antibodies, detectable 7-8 months after the third dose. Trial registry: https://rpcec.sld.cu/trials/RPCEC00000347

scholarly journals Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).

2021 ◽  
Author(s):  
Francisco Hernandez-Bernal ◽  
Maria del Carmen Ricardo-Cobas ◽  
Yenima Martin-Bauta ◽  
Zadis Navarro-Rodriguez ◽  
Marjoris Pinera-Martinez ◽  
...  
Keyword(s):  
Placebo Group ◽  
Neutralizing Antibodies ◽  
Phase 1 ◽  
Vaccination Schedule ◽  
Phase 2 ◽  
Igg Antibodies ◽  
Protein Vaccine ◽  
Double Blind ◽  
Double Blind Placebo ◽  
The Third

Aim: To evaluate the safety and immunogenicity of a SARS-CoV-2 recombinant spike protein vaccine (Abdala), administered intramuscularly in different strengths and vaccination schedules. Method: A phase 1-2, randomized, double-blind, placebo-controlled trial was done. Subjects were randomly distributed in 3 groups: placebo, 25 and 50 μg RBD. The product was applied intramuscularly, 0.5 mL in the deltoid region. During the first phase, two immunization schedules were studied: short (0-14-28 days) and long (0-28-56 days). In phase 2, only the short scheme was evaluated. The main endpoints were: safety and proportion of subjects with seroconversion of anti-RBD IgG antibodies to SARS-CoV-2. Blood samples were collected in several points according to the corresponding vaccination schedule to determine the level of RBD-specific IgG antibodies (seroconversion rates and geometric mean of the titers), the percentage of inhibition of RBD-ACE-2 binding and levels of neutralizing antibodies. Results: The product was well tolerated. Severe adverse events were not reported. Adverse reactions were minimal, mostly mild and local (from the injection site), resolved in the first 24-48 hours without medication. In phase 1, at day 56 (28 days after the third dose of the short vaccination schedule, 0-14-28 days) seroconversion of anti-RBD IgG was seen in 95.2 % of the participants (20/21) for the 50 μg group and 81 % of the participants (17/21) for the 25 μg group, and none in the placebo group (0/22); whereas neutralizing antibodies to SARS-CoV-2 were seen in 80 % of the participants (8/10) for the 50 μg group and 94.7% of the participants (18/19) for the 25 μg group. For the long schedule, at day 70 (14 days after the third dose) seroconversion of anti-RBD IgG was seen in 100% of the participants (21/21) for the 50 μg group and 94.7% of the participants (18/19) for the 25 μg group, and none in the placebo group (0/22); whereas neutralizing antibodies to SARS-CoV-2 were seen in 95 % of the participants (19/20) for the 50 μg group and 93.8% of the participants (15/16) for the 25 μg group In phase 2, at day 56 seroconversion of anti-RBD IgG was seen in 89.2% of the participants (214/240) for the 50 μg group, 77.7% of the participants (185/238) for the 25 μg group, and 4.6% in the placebo group (11/239); whereas neutralizing antibodies to SARS-CoV-2 were seen in 97.3% of the participants (146/150) for the 50 μg group and 95.1% of the participants (58/61) for the 25 μg group. Conclusion: Abdala vaccine against SARS-CoV-2 was safe, well tolerated and induced humoral immune responses against SARS-CoV-2 among adults from 19 to 80 years of age.

scholarly journals Evaluation of the Effectiveness of the Iralvex Gel on the Recurrent Aphthous Stomatitis Management

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Heidar Khademi ◽  
Pedram Iranmanesh ◽  
Ali Moeini ◽  
Atefeh Tavangar
Keyword(s):  
Clinical Trial ◽  
Placebo Group ◽  
Complete Healing ◽  
Recurrent Aphthous Stomatitis ◽  
Aphthous Stomatitis ◽  
The Other ◽  
Definitive Treatment ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Pain Duration

Introduction. As there is no definitive treatment for the recurrent aphthous stomatitis (RAS), most of the available therapies aim at decreasing pain and discomfort. The aim of this study was to investigate the effectiveness of the Iralvex gel on the RAS management. Material and Methods. In this double-blind and placebo-controlled clinical trial study, twenty patients were treated with the Iralvex gel and the other twenty patients were treated with placebo. In every participant complete healing of lesions, pain duration, and intensity were evaluated. Data were analyzed by independent t-test and analysis of variance. Results. Pain was relieved after 6.10 ± 0.29 days in the Iralvex group in comparison to 8.00 ± 0.33 days in the placebo group (P value ≤0.001). Complete remission in the Iralvex group was after 6.80 ± 0.27 days and 10.20 ± 0.42 days in the placebo group (P value ≤ 0.001). Furthermore, significant differences in the pain intensity between Iralvex and placebo group measured on days 1, 3, and 5 were obtained (P value ≤ 0.01). Conclusion. The results of this study show that Iralvex gel is effective and cheap remedy for treatment of RAS without side effects. This trial is registered with IRCT201207253251N3.

TREATMENT OF RAYNAUD SYNDROMES WITH PIRACETAM(NOOTROPIL R),NOOTROPIC AND ANIPLATELET AGENT

1987 ◽  
Author(s):  
M Moriau ◽  
E Lavenne-Pardonge ◽  
C H Col-De Beys
Keyword(s):  
Systemic Disease ◽  
The Other ◽  
Optimal Dosage ◽  
Double Blind Study ◽  
Inhibiting Activity ◽  
Synergic Effect ◽  
Double Blind ◽  
The Third ◽  
Daily Aspirin ◽  
Platelet Functions

Three prospective studies have been performed with piracetam (Nootropil ®-) in the treatment of Raynaud disease and syndromes.The first one, realized in 20 cases of Raynaud disease established that 8 g piracetam daily was the optimal dosage necessary to obtain a significant clinical, ultrasonic and biologic improvement.In the second one, 58 cases of Raynaud syndromes (47 idiopathic and 11 associated with systemic disease) were treated with 8 g daily piracetam during 6 to 12 months. A clinical and ultrasonic improvement was observed in 75 and 80 % of the cases and a normalisation of the disturbed platelet functions (36/58) in 88 %. Moreover a benefic rheologic effect was noted and related to the membrane deformability, the antiplatelet and the Von Willebranc factor synthese or release inhibiting activity of piracetamThe third one realized in cross over in 30 cases of Raynaud syndromes compare the effects of piracetam alone (dosage 8 g daily) with the combination piracetam (4 g daily) - aspirin (100 mg daily) or with other drugs like buflomedil, calcium antagonists and ketanserine.A synergic effect was obtained with the combination piracetam -aspirine and piracetam alone seems to be more efficient than the other drugs.A fourth double blind study is actually performed

scholarly journals A Comparative Study on the Effects of Ketofol, Dexmedetomidine, and Isofol in Anesthesia of Candidates for Dilatation and Curettage

2022 ◽  
Vol 11 (6) ◽  
Author(s):  
Mahzad Yousefian ◽  
Ali Mohammadian Erdi ◽  
Negin Haghshenas
Keyword(s):  
The Other ◽  
Blood Oxygen ◽  
Hemodynamic Changes ◽  
Blood Oxygen Saturation ◽  
Double Blind ◽  
The Third ◽  
Dilatation And Curettage ◽  
Double Blind Clinical Trial ◽  
Class 1 ◽  
Control Pain

Background: Dilatation and curettage (D & C) is one of the relatively common surgeries among women. Familiarity with the analgesics, along with their different uses and specific characteristics, can help to determine the best and most appropriate drug to control pain in the patients. Objectives: This study aimed to compare the effects of ketofol, dexmedetomidine, and isofol in anesthesia of candidates for D & C. Methods: In this double-blind clinical trial, 150 candidates for D & C surgeries with ASA class 1 and 2 were included. Patients were randomly divided into three groups. The first group received ketamine + propofol, the second group received dexmedetomidine, and the third group received isofol (isoflurane + propofol). Any hemodynamic changes or respiratory disorders, including apnea or hypoventilation, drop in the level of blood oxygen saturation, and the need for respiratory support, were recorded and compared. Results: Hypoventilation was observed in 47 patients in isofol group, 18 in the dexmedetomidine group, and 42 in ketofol group. Also, 48 patients in the isofol group, eight in the dexmedetomidine group, and 33 in the ketofol group experienced apnea. Moreover, 17 patients in the dexmedetomidine group, 35 in the ketofol group, and eight in the isofol group experienced bradycardia. The rate of bradycardia was significantly higher in the dexmedetomidine group (70%) compared to the other two groups, and the rate of hypotension was significantly higher in the isofol group (P = 0.001). Conclusions: According to the results, dexmedetomidine was associated with fewer complications during general anesthesia in D & C surgery.

scholarly journals Adverse effects of pharmacological therapy of benign prostatic hyperplasia on sexual function in men

2015 ◽  
Vol 143 (5-6) ◽  
pp. 284-289 ◽  
Author(s):  
Nebojsa Stojanovic ◽  
Ivan Ignjatovic ◽  
Nebojsa Djenic ◽  
Dragan Bogdanovic
Keyword(s):  
Side Effects ◽  
Adverse Effects ◽  
Sexual Function ◽  
Combined Therapy ◽  
Pharmacological Therapy ◽  
Dominant Mode ◽  
Control Group ◽  
Voiding Symptoms ◽  
Male Sexual Function ◽  
A Prospective Study

Introduction. The development of effective medications makes pharmacological therapy of BPH the dominant mode of treatment today. It improves urinary symptoms and prevents disease progression while producing side effects on male sexual function. Objective. The aim of the study is to present the effects of BPH pharmacological treatment on the occurrence of sexually adverse effects in men: changes in sexual desire, erectile, ejaculatory and the orgasmic function. Methods. A prospective study involving 156 BPH patients. The average age was 61.16?2.97. Four groups of 39 patients each were formed. The 4 groups were administered tamsulosin (alpha-blocker), finasteride (5-alpha reductase inhibitor), combination therapy (tamsulosin and finasteride) respectively, while the control group received no treatment. IPSS-QoL, IIEF and MSHQ-EjD questionnaires were used to evaluate the symptoms of voiding and sexual function. Follow-up examinations were performed 3 and 6 months into treatment. Results. Voiding symptoms improved in all groups receiving therapy. The side effects on the sexual function in all these groups include significant disorders of ejaculation and the orgasmic function. Ejaculation disorders: tamsulosin (-4.38?2.55; p<0.001), combined therapy (-3.89?2.84) and finasteride (-1.49?2.52). Orgasmic function disorders: tamsulosin (-1.03?1.94), combined therapy (-0.76?2.07) and finasteride (-0.54?1.68). Complete absence of ejaculation was experienced by 23% of patients on combined therapy, 15% on tamsulosin and 5% on finasteride. Conclusion. Pharmacological therapy of BPH improved voiding symptoms producing different effects on male sexual function. The main adverse effect on sexual function in men is the deterioration in ejaculation or the absence thereof. Clinical consideration of BPH should include the elements of male sexual function, patients? age, the characteristics and effects of each group of drugs.

The Effect of Warfarin Sodium on the Duration of Platelet Aggregation

1967 ◽  
Vol 18 (03/04) ◽  
pp. 766-778 ◽  
Author(s):  
H. J Knieriem ◽  
A. B Chandler
Keyword(s):  
Platelet Count ◽  
Placebo Group ◽  
Platelet Aggregation ◽  
Prothrombin Time ◽  
Platelet Rich Plasma ◽  
Healthy Adults ◽  
Double Blind Study ◽  
Double Blind ◽  
Warfarin Sodium

SummaryThe effect of the administration of warfarin sodium (Coumadin®) on the duration of platelet aggregation in vitro was studied. Coumadin was given for 4 consecutive days to 10 healthy adults who were followed over a period of 9 days. The duration of adenosine diphosphate-induced platelet aggregation in platelet-rich plasma, the prothrombin time, and the platelet count of platelet-rich plasma were measured. Four other healthy adults received placebos and participated in a double-blind study with those receiving Coumadin.Although administration of Coumadin caused a prolongation of the prothrombin time to 2 or 21/2 times the normal value, a decrease in the duration of platelet aggregation was not observed. In most individuals who received Coumadin an increase in the duration of platelet aggregation occurred. The effect of Coumadin on platelet aggregation was not consistently related to the prothrombin time or to the platelet count. In the placebo group there was a distinct relation between the duration of platelet aggregation and the platelet count in platelet-rich plasma.The mean increase in the duration of platelet aggregation when compared to the control value before medication with Coumadin was 37.7%. In the placebo group there was a mean increase of 8.4%. The difference between the two groups is significant (p <0.001). Increased duration of platelet aggregation also occurred in two individuals who received Coumadin over a period of 10 and 16 days respectively.

Efficacy of some insecticide modules against major insect pests and spider population of rice, Oryza sativa L.

ENTOMON ◽  
2018 ◽  
Vol 43 (4) ◽  
pp. 257-262
Author(s):  
Atanu Seni ◽  
Bhimasen Naik
Keyword(s):  
Oryza Sativa ◽  
Grain Yield ◽  
Untreated Control ◽  
Insect Pests ◽  
Oryza Sativa L ◽  
Gall Midge ◽  
Stem Borer ◽  
The Other ◽  
The Third ◽  
Treated Plot

Experiments were carried out to assess some insecticide modules against major insect pests of rice. Each module consists of a basal application of carbofuran 3G @ 1 kg a.i ha-1 at 20 DAT and Rynaxypyr 20 SC @ 30 g a.i ha-1 at 45 DAT except untreated control. All modules differ with each other only in third treatment which was applied in 65 DAT. The third treatment includes: Imidacloprid 17.8 SL @ 27 g a.i ha-1, Pymetrozine 50 WG @ 150 g a.i ha-1, Triflumezopyrim 106 SC @ 27 g a.i ha-1, Buprofezin 25 SC @ 250 g a.i ha-1; Glamore (Imidacloprid 40+Ethiprole 40% w/w) 80 WG @ 100 g a.i. ha-1, Thiacloprid 24 SC @ 60 g a.i ha-1, Azadirachtin 0.03 EC @ 8 g a.i ha-1, Dinotefuran 20 SG@ 40 g a.i ha-1 and untreated control. All the treated plots recorded significantly lower percent of dead heart, white ear- head caused by stem borer and silver shoot caused by gall midge. Module with Pymetrozine 50 WG @ 150 g a.i ha-1 treated plot recorded significantly higher per cent reduction of plant hoppers (>80% over untreated control) and produced higher grain yield (50.75 qha-1) than the other modules. Among the different treated modules the maximum number of spiders was found in Azadirachtin 0.03 EC @ 8 g a.i ha-1 treated module plot followed by other treatments.

Retroaktive Neuverhandlung

2018 ◽  
Vol 63 (1) ◽  
Author(s):  
Daniel Martin Feige
Keyword(s):  
Original Work ◽  
The Other ◽  
Final Part ◽  
Critical Reading ◽  
The Third ◽  
Works Of Art ◽  
The Relationship

Der Beitrag widmet sich der Frage historischer Folgeverhältnisse in der Kunst. Gegenüber dem Gedanken, dass es ein ursprüngliches Werk in der Reihe von Werken gibt, das späteren Werken seinen Sinn gibt, schlägt der Text vor, das Verhältnis umgekehrt zu denken: Im Lichte späterer Werke wird der Sinn früherer Werke neu ausgehandelt. Dazu geht der Text in drei Schritten vor. Im ersten Teil formuliert er unter der Überschrift ›Form‹ in kritischer Abgrenzung zu Danto und Eco mit Adorno den Gedanken, dass Kunstwerke eigensinnig konstituierte Gegenstände sind. Die im Gedanken der Neuverhandlung früherer Werke im Lichte späterer Werke vorausgesetzte Unbestimmtheit des Sinns von Kunstwerken wird im zweiten Teil unter dem Schlagwort ›Zeitlichkeit‹ anhand des Paradigmas der Improvisation erörtert. Der dritte und letzte Teil wendet diese improvisatorische Logik unter dem Label ›Neuaushandlung‹ dann dezidiert auf das Verhältnis von Vorbild und Nachbild an. The article proposes a new understanding of historical succession in the realm of art. In contrast to the idea that there is an original work in the series of works that gives meaning to the works that come later, the text proposes to think it exactly the other way round: in the light of later works, the meanings of earlier works are renegotiated. The text proceeds in three steps to develop this idea. Under the heading ›Form‹ it develops in the first part a critical reading of Danto’s and Eco’s notion of the constitution of the artworks and argues with Adorno that each powerful work develops its own language. In the second part, the vagueness of the meaning of works of art presupposed in the idea of renegotiating earlier works in the light of later works is discussed under the term ›Temporality‹ in terms of the logic of improvisation. The third and final part uses this improvisational logic under the label ›Renegotiation‹ to understand the relationship between model and afterimage in the realm of art.

Sign in / Sign up

Export Citation Format

Share Document